Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2001-12-05
2009-12-08
Lewis, Patrick T (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S123100
Reexamination Certificate
active
07629330
ABSTRACT:
The invention relates to three-dimensional molecular structure determination of polymers, three-dimensional computer molecular modeling, rational drug design, and immunomodulatory polymers. In particular the invention is directed to immunomodulatory polymers, as well as to methods for designing, selecting, and screening therapeutic agents having immunomodulatory activity.
REFERENCES:
patent: 5331573 (1994-07-01), Balaji et al.
patent: 5679654 (1997-10-01), Tzianabos et al.
patent: 5700787 (1997-12-01), Tzianabos et al.
patent: 5888741 (1999-03-01), Hendry
patent: 6110672 (2000-08-01), Mandel et al.
patent: WO 00/59515 (2000-10-01), None
Comstock et al. Journal of Bacteriology (1999), vol. 181, pp. 6192-6196.
Brubaker et al. The Journal of Immunology (1999), vol. 162, pp. 2235-2242.
Baumann H et al., “Structural elucidation of two capsular polysaccharides from one strain ofBacteroides fragilisusing high-resolution NMR spectroscopy,”Biochemistry(1992) 31:4081-89.
Brubaker JO et al., “Mitogenic activity of purified capsular polysaccharide A fromBacteroides fragilis: differential stimulatory effect on mouse and rat lymphocytes in vitro,”J. Immunol. (1999) 162:2235-42.
Comstock LE et al., “Interstrain variation of the polysaccharide B biosynthesis locus ofBacteroides fragilis: characterization of the region from strain 638R,”J. Bacteriol. (1999) 181:6192-96.
Coyne MJ et al.,Bacteroides fragilisNCTC9343 produces at least three distinct capsular polysaccharides: cloning, characterization, and reassignment of polysaccharide B and C biosynthesis loci.Infect Immun. Nov. 2000;68(11):6176-81.
Dahiyat BI. et al., “De novo protein design: fully automated sequence selection,”.Science(1997) 278:82-87.
Hirata N et al., “Cytokine synthesis of human monocytes stimulated by triple of single helical conformer of an antitumour (1→3)-beta-D-glucan preparation, sonifilan.”Zentralbl Bakteriol(1998) 288:403-13. Abstract.
Kalka-Moll WM et al., “Effect of molecular size on the ability of zwitterionic polysaccharides to stimulate cellular immunity,”J. Immunol(2000) 164:719-24.
Kulicke WM et al., “Correlation between immunological activity, molar mass, and molecular structure of different (1→3)-beta-D-glucans.”Carbohydr. Res(1997) 297:135-43. Abstract.
Ohno N et al., “Enhancement of LPS triggered TNF-alpha (tumor necrosis factor-alpha) production by (1→3)-beta-D-glucans in mice.” Biol. Pharm. Bull (1995) 18:126-33.
Ohno N et al., “Comparison of the immunopharmacological activities of triple and single-helical schizophyllan in mice.”Biol. Pharm Bull(1995) 18:1242-47.
Pantosti A et al., “Immunochemical characterization of two surface polysaccharides ofBacteroides fragilis,” Infect Immun. (1991) 59:2075-82.
Schneider G et al., “De novo design of molecular architectures by evolutionary assembly of drug-derived building blocks.”J. Computer-Aided Mol. Design(2000) 14:487-94.
Stein KE, “Thymus-independent and thymus-dependent responses to polysaccharide antigens,”J. Infect. Dis(1992) 165:S49-S52.
Tzianabos AO et al., “Structural features of polysaccharides that induce intra-abdominal abscesses,”Science(1993) 262:416-19.
Tzianabos AO et al., “Polysaccharide-mediated protection against abscess formation in experimental intra-abdominal sepsis,”J Clin. Invest. (1995) 96:2727-31.
Tzianabos AO et al., “Structural characteristics of polysaccharides that induce protection against intra-abdominal abscess formation,”Infect Immun(1994) 62:4881-86.
Tzianabos AO et al., “T cells activated by zwitterionic molecules prevent abscesses induced by pathogenic bacteria,”J. Biol. Chem. (2000) 275: 6733-40.
Tzianabos AO et al., “The capsular polysaccharide ofBacteroides fragiliscomprises two ionically linked polysaccharides,”J. Biol. Chem. (1992) 267:18230-35.
Wang Y et al., “Structural basis of the abscess-modulating polysaccharide A2 fromBacteroides fragilis,” Proc Natl Acad Sci USA(2000) 97:13478-83.
Wang Y et al., “Structure characterization of an abscessogenic capsular polysaccharide fromBacteriodes fragilisby NMR spectroscopy.” IXI Int'l Conference of NMR in Biological Systems, Florence, Italy, Aug. 20-25, 2000. Abstract.
Kasper Dennis L.
Roehrl Michael H.
Wang Ying
Lewis Patrick T
The Brigham and Women's Hospital, Inc.
Wolf Greenfield & Sacks P.C.
LandOfFree
Use of zwitterionic polysaccharides for the specific... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of zwitterionic polysaccharides for the specific..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of zwitterionic polysaccharides for the specific... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4106727